Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis Mease, P., Smolen, J., Kavanaugh, A., Nash, P., Gallo, G., Liu-Leage, S., Sapin, C., Genovese, M., Bessette, L. J RHEUMATOL PUBL CO. 2021: 1167

View details for Web of Science ID 000680554800184